OBI Pharma Inc (台灣浩鼎) shares yesterday rose 2.29 percent following a two-day slump, after the biotech firm cleared up rumors of irregularities in the provision of stock compensation to interested parties.
Shares of OBI Pharma closed at NT$670 in Taipei trading, following declines of 2.51 percent and 6.43 percent in the past two sessions.
The company dismissed rumors that it had granted shares to Academia Sinica president Wong Chi-huey (翁啟惠), who later transferred the shares to company chairman Michael Chang (張念慈).
Academia Sinica, the nation’s leading research academy, works in close collaboration with OBI Pharma.
OBI Pharma was founded by Chang and Wong as a wholly owned subsidiary of US-based Optimer Pharmaceuticals Inc in April of 2012. Optimer Pharmaceuticals ousted Chang, who had served as chairman at OBI Pharma, on suspicion that Chang had arranged for a grant of 1.5 million OBI Pharma shares to himself for the benefit of a third party.
OBI Pharma said that throughout the company’s history, it has never approved share grants for members of its research team, management or interested parties.
In addition, the company said that Wong was not involved in Optimer Pharmaceutical’s October 2012 decision to sell the remaining stakes of its former subsidiary back to OBI Pharma shareholders and that Chang was later cleared of wrongdoing following probes by US financial regulators.
Chang had no control on prices in the selling of shares, which was initiated by Optimer to raise funds, OBI Pharma said, adding that the rumors are aimed at stirring controversy over the ownership of the company’s OBI-822 medicine, a promising active immunotherapy for metastatic breast cancer, after its share prices soared, while vowing to take legal action over unfounded rumors.
OBI Pharma last month announced that it has inked an agreement to transfer exclusive rights for Merck & Co Inc of the US to develop and commercialize the company’s narrow spectrum antibiotic Dificid in Taiwan.
Dificid has been approved by Taiwanese authorities to treat closridium difficile-related diarrhea in adults.
In related news, TaiGen Biotechnology Co (太景生技) shares yesterday gained 7.71 percent to climb to NT$37 after the company announced that its pneumonia drug Taigexyn is going through phase-three clinical trials and that a new drug application would be submitted to the Chinese Food and Drug Administration next year.
The news came after TaiGen said last week it had received approval from the Chinese agency for the phase-two clinical trial of Burixafor, an autologous hematopoietic stem-cell transplantation drug.
So far this year, TaiGen shares have dropped 4.27 percent on the Taipei Exchange, outperforming the over-the-counter benchmark index, which has dropped 6.35 percent over the same period.
EXTRATERRITORIAL REACH: China extended its legal jurisdiction to ban some dual-use goods of Chinese origin from being sold to the US, even by third countries Beijing has set out to extend its domestic laws across international borders with a ban on selling some goods to the US that applies to companies both inside and outside China. The new export control rules are China’s first attempt to replicate the extraterritorial reach of US and European sanctions by covering Chinese products or goods with Chinese parts in them. In an announcement this week, China declared it is banning the sale of dual-use items to the US military and also the export to the US of materials such as gallium and germanium. Companies and people overseas would be subject to
DOLLAR CHALLENGE: BRICS countries’ growing share of global GDP threatens the US dollar’s dominance, which some member states seek to displace for world trade US president-elect Donald Trump on Saturday threatened 100 percent tariffs against a bloc of nine nations if they act to undermine the US dollar. His threat was directed at countries in the so-called BRICS alliance, which consists of Brazil, Russia, India, China, South Africa, Egypt, Ethiopia, Iran and the United Arab Emirates. Turkey, Azerbaijan and Malaysia have applied to become members and several other countries have expressed interest in joining. While the US dollar is by far the most-used currency in global business and has survived past challenges to its preeminence, members of the alliance and other developing nations say they are fed
TECH COMPETITION: The US restricted sales of two dozen types of manufacturing equipment and three software tools, and blacklisted 140 more Chinese entities US President Joe Biden’s administration unveiled new restrictions on China’s access to vital components for chips and artificial intelligence (AI), escalating a campaign to contain Beijing’s technological ambitions. The US Department of Commerce slapped additional curbs on the sale of high-bandwidth memory (HBM) and chipmaking gear, including that produced by US firms at foreign facilities. It also blacklisted 140 more Chinese entities that it accused of acting on Beijing’s behalf, although it did not name them in an initial statement. Full details on the new sanctions and Entity List additions were to be published later yesterday, a US official said. The US “will
COLLABORATION: The operations center shows the close partnership between Taiwan and Japan in the field of semiconductors, Minister of Economic Affairs J.W. Kuo said Tokyo Electron Ltd, Asia’s biggest semiconductor equipment supplier, yesterday launched a NT$2 billion (US$61.5 million) operations center in Tainan as it aims to expand capacity and meet growing demand. Its new Taiwan Operations Center is expected to help customers release their products faster, boost production efficiency and shorten equipment repair time in a cost-effective way, the company said. The center is about a five-minute drive from the factories of its major customers such as Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) advanced 3-nanometer and 2-nanometer fabs. The operations center would have about 1,000 employees when it is fully utilized, the company
RSS